All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
During the AML Hub Steering Committee meeting held on May 17, 2023, Charles Craddock chaired a discussion on optimizing transplant outcomes in patients allografted for acute myeloid leukemia, with contributions from Gail Roboz, Selina Luger, Jorge Sierra, Naval Daver, and Jeffrey Lancet.
Optimizing transplant outcomes in patients allografted for AML
Craddock discusses the optimal selection of patients for transplant and strategies to improve outcomes in patients who are candidates for transplant, with a particular focus on conditioning regimens. He highlights the US-CTN 0901 study comparing myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) regimens and the FIGARO trial assessing intensified RIC regimens. The committee discusses the timing and selection of patients for transplant and the difference in patients’ and clinicians’ perceptions of the chance of a cure. They also discuss the need for randomized trials assessing transplantation and factors that affect transplant outcomes, the optimal design of these trials, and the value of data sharing between centers. They raise the need for the standardization of the status of patients going to transplant.
What time is the right time for transplantation?
On June 29, 2023, the AML Hub hosted a discussion on “What time is the right time for transplantation?”, chaired by Selina Luger, with contributions from Gert Ossenkoppele, Jeffrey Lancet, Yasushi...
Impact of allo-HSCT and Fried’s frailty phenotype in older patients with AML
We summarize a study assessing the benefits of allo-HSCT in older patients with AML and a study evaluating the impact of Fried’s frailty phenotype on survival outcomes...
Subscribe to get the best content related to AML delivered to your inbox